This technology includes isolate of Middle East respiratory syndrome coronavirus (MERS-CoV) for antiviral and diagnostic development. The isolate was confirmed by full genome sequencing and further characterized by serologic and molecular testing and electron-microscopical studies. This is the first MERS-CoV strain isolated from a US imported case of MERS.
This technology includes combinations of currently approved antiretrovirals (ARVs) which could allow for simpler dosing regimens that improve adherence to HIV prevention strategies. Event-Driven PrEP (ED-PrEP) with 2 oral doses of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) taken 2-24 hours before sex, a 3rd dose 24 hours after sex, and a 4th dose 48 hours after sex (2+1+1) is considered as a PrEP option by the World Health Organization for men who have sex with men (MSM). Recommended post-exposure prophylaxis (PEP) regimens require 28 days of daily oral dosing.
This technology includes HIV clones to develop proteomic microarrays for HIV research. The microarray chip can be used to monitor the antibody response to all proteins and many epitopes of HIV-1.
This technology includes Klebsiella pneumoniae isolate to be used for research studies and diagnostic tests to detect antimicrobial resistance.
This technology includes an Escherichia coli isolate to be used in for research purposes and the development of diagnostics. The isolate is unique because it has the mcr-1 gene.
This technology includes an isolate of the yeast species Candida auris to be used in the development of diagnostic tools or anti-fungal for therapeutic use.
This technology includes a vaccine for immunizing against different strains of rotavirus. Rotavirus is a highly contagious virus causing severe diarrhea in children and can be fatal. Due to various circumstances, the number of available, efficacious vaccines for rotavirus is declining at a time when infections remain a serious worldwide problem. This technology meets the need for vaccines against human rotavirus A strains of both common and less common types.
This technology includes a combined IPV and IRV for co-administration and global immunization against polio and rotavirus among children. Currently IPV and IRV are administered by parenteral administration in two separate injections, which complicates routine immunization schedules and is costly.
This technology includes Borrelia hermsii isolate for diagnostic development of serologic tests. Borrelia hermsii is the major identified cause of Tick-Borne Relapsing Fever (TBRF) in humans in the western United States. Initial signs and symptoms of infection include fever, nausea, headache and malaise. Most cases are diagnosed on clinical suspicion and epidemiologic risk. Common source, case clusters notable. Microscopy and serologic detection of antibody responses to infection may aid in the laboratory confirmation or infection.
This technology includes natural Yellow Fever Virus, Zika Virus, and Powassan Virus isolates for various uses in research and development of diagnostics and immunizations.